LifeVantage Corporation announced its financial results for the fourth fiscal quarter and full fiscal year 2026. Revenue during the fourth fiscal quarter was $42.4 million, down 23.1% year-over-year, with an adjusted EBITDA of $2.7 million. Net income per diluted share was $0.10, compared to $0.15 per diluted share in the year-ago period.
For the full fiscal year 2026, revenue was $182.6 million, a 20.1% year-over-year decrease, with adjusted EBITDA of $13.7 million, down from $22.1 million in full fiscal 2025. Revenue in the Americas during this time fell 23.2% year-over-year, while revenue in Asia/Pacific and Europe decreased by 6.9%. The company attributed this decrease to a decline in sales of the MindBody GLP-1 System, as well as declines in order number and size, but the effects of this decline were partially offset by sales of LoveBiome, which the company acquired in October 2025.
“It’s a privilege to lead LifeVantage at this stage of its journey and my conviction about this company is stronger today than when I accepted the role,” said Terrence Moorehead, LifeVantage President and Chief Executive Officer. “With a differentiated, science-backed platform, strong gross margins and a debt-free balance sheet, our foundation is strong and I believe we have a real competitive advantage. Our early focus will be on strengthening the LifeVantage brand, building a more relevant consumer proposition and driving operational excellence. Despite the challenges reflected in our recent results, I’m optimistic about what lies ahead. We intend to move forward with a real sense of urgency and look forward to sharing more about our strategy as our work progresses.”
Operating income for fiscal 2026 was $6.1 million, down from $12.2 million in fiscal 2025. The company generated $10.2 million of cash from operations during fiscal 2026 and ended the period with cash and cash equivalents of $14.9 million with no debt outstanding.
